Acetaminophen, Some other Drugs, Some Diseases and the Risk of Transitional Cell Carcinoma: A population-based case-control study

References

• Parkin D M, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594–606
   PubMed Web of Science ®Google Scholar
• IARC. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. IARC, Lyon 1987, Supplement 7
   Google Scholar
• Morrison A S, Cole P. Urinary tract. Cancer epidemiology and prevention, D Schottenfeld, J F J Fraumeni. W.B. Saunder Co., Philadelphia 1987; 925–37
   Google Scholar
• Steineck G, Plato N, Gerhardsson M, Norell S E, Hogstedt C. Increased risk of urothelial cancer in Stockholm during 1985–87 after exposure to benzene and exhausts. Int J Cancer 1990; 45: 1012–7
   PubMed Web of Science ®Google Scholar
• Steineck G, Hagman U, Gerhardsson M, Norell S E. Vitamin A supplements, fried foods, fat and urothelial cancer. A case‐referent study in Stockholm in 1985–87. Int J Cancer 1990; 45: 1006–11
   PubMed Web of Science ®Google Scholar
• Hultengren N, Lagergren C, Ljungqvist A. Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand 1965; 13: 314–20
   Google Scholar
• IARC. Some pharmaceutical drugs. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. IARC, Lyon 1980; 24
   Google Scholar
• Johansson S L. Carcinogenicity of analgesics: long‐term treatment of Sprague‐Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer 1981; 27: 521–9
   PubMed Web of Science ®Google Scholar
• Flaks B, Flaks A, Shaw A P. Induction by paracetamol of bladder and liver tumours in the rat. Effects on hepatocyte fine structure. Acta Pathol Microbiol Immunol Scand 1985; 93: 367–71
   Google Scholar
• Mahony J F, Storey B G, Ibanez R C, Stewart J H. Analgesic abuse, renal parenchymal disease and carcinoma of the kidney or ureter. Aust NZJ Med 1971; 7: 463–9
   Google Scholar
• Thun M J, Namboodiri M M, Heath C W, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6
   PubMed Web of Science ®Google Scholar
• Thun M J, Namboodiri M M, Calle E E, Flanders W D, Heath C W, Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322–7
   PubMed Web of Science ®Google Scholar
• Greenberg E R, Baron J A, Freeman D H J, Mandel J S, Haile R. Reduced risk of large‐bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993; 85: 912–6
   PubMedGoogle Scholar
• Baron J A, Greenberg E R. Could aspirin really prevent colon cancer? N Engl J Med 1991; 325: 1644–6
   Google Scholar
• Deutsch M E. Aspirin use and reduced risk of fatal colon cancer (letter). N Engl J Med 1992; 326: 1289
   PubMedGoogle Scholar
• Travers J D, Temple A R, Gates T N. Aspirin use and reduced risk of fatal colon cancer (letter). N Engl J Med 1992; 326: 1289–90
   PubMedGoogle Scholar
• Marnett L J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575–89
   PubMed Web of Science ®Google Scholar
• Breslow N E, Day N E. Statistical methods in cancer research. The analysis of case‐control studies. IARC Scientific Publ. No. 32, IARC, Lyon 1980; 191–279
   Google Scholar
• McCredie M, Stewart J H, Day N E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 1993; 53: 245–9
   PubMed Web of Science ®Google Scholar
• Ross R K, Paganini‐Hill A, Landolph J, Gerkins V, Henderson B E. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Cancer Res 1989; 49: 1045–8
   PubMedGoogle Scholar
• Piper J M, Tonascia J, Matanoski G M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313: 292–5
   PubMedGoogle Scholar
• Sakata T, Hasegawa R, Johansson S L, Zenser T V, Cohen S M. Inhibition by aspirin of N‐:4–(5–nitro‐2–furyl)‐2–thiazolyl:formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res 1986; 46: 3903–6
   PubMed Web of Science ®Google Scholar
• Cohen S M, Hasegawa R, Sakata T, Johansson S L. Effect of aspirin on urinary bladder carcinogenesis initiated with N‐:4–(5–nitro‐2–furyl)‐2–thiazolyl:formamide in rats. Cancer Res 1989; 49: 372–7
   PubMedGoogle Scholar
• Kinlen L J, Willows A N, Goldblatt P, Yudkin J. Tea consumption and cancer. Br J Cancer 1988; 58: 397–401
   PubMed Web of Science ®Google Scholar
• Patierno S R, Lehman N L, Henderson B E, Landolph J R. Study of the ability of phenacetin, acetaminophen, and aspirin to induce cytotoxicity, mutation and morphological transformation in C3H/10T1/2Clone 8 mouse embryo cells. Cancer Res 1989; 49: 1038–44
   PubMedGoogle Scholar
• Jensen O M, Knudsen J B, Tomasson H, Ssrensen B L. The Copenhagen case‐control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer 1989; 44: 965–8
   PubMed Web of Science ®Google Scholar
• Steineck G, Ahlbom A. A definition of bias founded on the concept of the study base. Epidemiol 1992; 3: 477–82
   PubMedGoogle Scholar
• Ahlbom A, Steineck G. Aspects of misclassification of confounding factors. Am J Ind Med 1992; 21: 107–12
   PubMed Web of Science ®Google Scholar
• Hasegawa R, Murasaki G, St. John M K, Zenser T V, Cohen S M. Evaluation of nitrofurantoin on the two stages of urinary bladder carcinogenesis in the rat. Toxicology 1990; 62: 333–47
   PubMedGoogle Scholar
• Dietz D D, Abdo K M, Haseman J K, Eustis S L, Huff J E. Comparative toxicity and carcinogenicity studies of tetracycline and oxytetracycline in rats and mice. Fundam Appl Toxicol 1991; 17: 335–46
   PubMedGoogle Scholar
• Kjaer S K, Knudsen J B, Sørensen B L, Jensen O M. The Copenhagen case‐control study of bladder cancer. V. Review of the role of urinary‐tract infection. Acta Oncol 1989; 28: 631–6
   PubMed Web of Science ®Google Scholar
• Plotz P H, Klippel J H, Decker J L, et al. Bladder complications in patients receiving cyclophosphamide for systeic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979; 91: 463–9
   Google Scholar
• Ansher A F, Melton J W, Sliwinski A J. Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis. Arthritis Rheum 1983; 26: 804–5
   PubMedGoogle Scholar
• Kinlen L J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44–9
   PubMed Web of Science ®Google Scholar
• Gridley G, McLaughlin J K, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–11
   PubMed Web of Science ®Google Scholar
• Katusic S, Beard C M, Kurland L T, Weis J W, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78: 505
   Google Scholar
• Isomäki H A, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978; 31: 691–6
   PubMedGoogle Scholar